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Milk fat globule membrane 
A B S T R A C T   
Functional nutrients like synbiotics or milk-fat globule membrane (MFGM) affect positively host immunity, 
modifying intestinal microbioma and reducing early childhood infections. We compared effects of an experi-
mental enriched-infant formula with long chain polyunsaturated fatty acids, MFGM, synbiotics, sialic acid, nu-
cleotides and gangliosides to a standard infant formula and breastfeeding regarding infections incidence and 
evolution in infants until 18 months of age. 170 healthy infants were enrolled in a RCT to receive either a 
bioactive functional nutrients enriched infant formula (EF, n = 85) or a standard formula (SF, n = 85). 50 
breastfed (BF) infants were also enrolled. At age 12 months, EF group compared to SF and BF groups showed a 
lower incidence of infectious episodes. Moreover, they also presented less incidence of respiratory tract infections 
and gastrointestinal infections than SF infants, reducing risk by 30.2% and 32.5%, respectively. Infants fed with 
an EF seem to have reduced incidence of certain infections at 12 months of age.   
1. Introduction 
Breastfeeding is the gold-standard for infant nutrition containing 
both nutritive and non-nutritive components. It is well known that BF 
protects newborns and infants against infections (Victora et al., 2016). 
Many components of human breast milk, including short-chain galacto- 
oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS), 
immunoglobulins, antibacterial enzymes, glycosylated proteins, anti-
viral lipids, and leukocytes (Sánchez et al., 2021), play an important role 
in development of infant immune response due to their ability to bind 
pathogenic bacteria, while promoting growth of protective enteric 
bacteria (Ballard & Morrow, 2013; Newburg, 2013). Moreover, breast 
milk also contains maternal pathogen-specific antibodies, which provide 
infants immune protection during their first months of life, a period in 
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which infantś immune system has not reached yet its full potential 
(Zhang et al., 2017); as well as other components, such as human milk 
oligosaccharides (HMOs), which favor development of a beneficial 
microbiota (Gopalakrishna & Hand, 2020; Lyons et al., 2020). Maternal 
leucocytes transferred by breast milk also seem to offer protection and 
enhance development of infants immune system (Laouar, 2020). How-
ever, it is not always possible or suitable to maintain breastfeeding along 
time. In that case, infant formulas have to be offered to satisfy infants’ 
nutritional and energy requirements. In this line, bioactive nutrients 
such as pre- and probiotic or milk fat globule membrane (MFGM) are 
currently being added to infant formulas to narrow the functional and 
nutritional gap between breast milk and infant formulas (Hernell et al., 
2016; Ratsika et al., 2021). In fact, there is evidence that supplemen-
tation with functional nutrients during early childhood might influence 
gut microbiota development, interfering on immune response in a pos-
itive way (Nauta et al., 2013). Both scGOS and lcFOS have shown to 
have prebiotic and immunomodulatory effects comparable to HMOs, 
reducing certain type of infections (Ballard & Morrow, 2013; Doherty 
et al., 2018; Triantis et al., 2018), particularly upper respiratory tract 
infections (RTI) (Gopalakrishna & Hand, 2020; Lyons et al., 2020). 
Prebiotics are capable to enhance growth of beneficial gut microbiota 
and, hence, may also provide a protective effect against allergic mani-
festations (Cheng et al., 2019), as well as to diminish infections duration 
(Neumer et al., 2021; Thai & Gregory, 2020). Long chain poly-
unsaturated fatty acids (LC-PUFAs) may have also a positive effect on 
immune maturation (Gottrand, 2008; Miles et al., 2021; Ramiro-Cortijo 
et al., 2020). 
Several probiotics have also shown a beneficial effect on typical 
childhood infections and immune-related diseases. For instance, Lacto-
bacillus rhamnosus GG (LGG) reduces risk of RTI and atopic dermatitis 
(Nermes et al., 2011; Rautava et al., 2009), while Bifidobacterium BB12, 
Streptococcus thermophilus (Phuapradit et al., 1999) and Bifidobacterium 
longum subsp. infantis CECT 7210, employed in our study formula, seem 
to be able to inhibit rotavirus infection (Muñoz et al., 2011). Other 
Bifidobacteria like Bifidobacterium longum BL999 may interfere posi-
tively in RTI (Puccio et al., 2007). Lactobacillus rhamnosus H001, another 
probiotic strain also included in our study formula, has shown a good 
safety profile in infants (Dekker et al., 2009) and beneficial effects in 
atopic eczema (Wickens et al., 2008). Furthermore, Bifidobacterium lactis 
BB12, Lactobacillus reuteri or Lactobacillus fermentum CECT5716 have 
been associated with reduction in both incidence and risk of diarrhea 
and RTI in infants (Maldonado et al., 2019; Rautava et al., 2009; 
Weizman et al., 2005). The combination of pre- and probiotics (syn-
biotics) shows a good evidence in reducing RTI (Chan et al., 2020). 
There is evidence suggesting that LC-PUFAs also contribute to a 
better immune response in infants (Gottrand, 2008; Thai & Gregory, 
2020). Several trials found evidence in infants fed with LC-PUFAs sup-
plementation to have a lower incidence regarding RTI, gastrointestinal 
infections (GII) and allergic manifestations (Lapillonne et al., 2014; 
Miles et al., 2021; Pastor et al., 2006). 
On the other hand, milk fat globule membrane (MFGM), a complex 
structure present in human and bovine milk (Liao et al., 2011; Reinhardt 
& Lippolis, 2006), contains a broad variety of integral and peripheral 
proteins, glycoproteins (butyrophilin, lactadherin, or mucins), enzymes, 
and lipids with antimicrobial and antiviral effects (Fuller et al., 2013; 
Peterson et al., 1998; Spitsberg, 2005). MFGM-enriched infant formulas 
seem to reduce incidence of acute otitis media (AOM) (Timby et al., 
2015) and diarrhea (Zavaleta et al., 2011) in young infants. According to 
a recent meta-analysis, MFGM are safe and data is pointing out to 
beneficial effects regarding infections (Ambrożej et al., 2021). There-
fore, there is broad evidence that infant formula supplemented with 
functional nutrients, such as MFGM, prebiotic, probiotic or both (syn-
biotics), each improves gut microbiome development, inducing immune 
response modulation and eventually reducing infection burden in in-
fants. The goal of the present study was to analyze effects of a novel 
combination of bioactive nutrients-enriched infant formula containing 
MFGM components, synbiotics (pre- and probiotics), LC-PUFAs, gan-
gliosides, nucleotides and sialic acid, on number and duration of in-
fections, need for health-care seeking, and infection related medication 
during the first 18 months of life in healthy infants, compared to those 
fed with a standard infant formula or breast milk. 
2. Methods 
2.1. Study design and subjects 
The COGNIS study (A Neurocognitive and Immunological Study of a 
New Formula for Healthy Infants) was designed as a prospective, ran-
domized double-blind, nutritional intervention study based on bioactive 
compounds-enriched infant formula (registered at www.ClinicalTrials. 
gov; Identifier: NCT02094547). Detailed information has been pub-
lished elsewhere (Nieto-Ruiz et al., 2019, 2020). Briefly, 220 healthy 
full-term babies were involved in the study; from these, 170 infants aged 
between 0 and 2 months old were randomized using a mathematical 
statistical method (ratio 1:1) to receive, during their first 18 months of 
life, either a standard infant formula (SF n = 85), or an experimental 
infant formula (EF n = 85) Additionally, 50 breast-fed (BF) infants were 
evaluated along 18 months of age as reference group. A detailed 
participant flowchart from baseline visit to 18 months is presented in 
Fig. 1. 
The current analysis included a total of 171 infants who attended the 
6 months visit (SF = 60; EF = 69; BF = 42), 152 at 12 months visit (SF =
51; EF = 63; BF = 38) and 141 infants at 18 months visit (SF = 48; EF =
56; BF = 37). 
Both standard (SF) and experimental (EF) infant formulas follow the 
guidelines of the European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) Committee of Nutrition and Eu-
ropean Food Safety Authority (EFSA) (Koletzko et al., 2005; Lázaro- 
Almarza & Benjamín, 2010), as well as international and national rec-
ommendations for the composition of infant formulas. A full description 
of the nutritional composition is detailed in Table 1. Briefly, EF was 
designed to contain functional nutrients, including MFGM components 
[10% of total protein content (wt:wt)]; synbiotics [mix of FOS and inulin 
(ratio 1:1), Bifidobacterium infantis IM1 and Lactobacillus rhamnosus LCS- 
742]; LC-PUFAs arachidonic acid (ARA) and docosahexaenoic acid 
(DHA); gangliosides; nucleotides and sialic acid. Both standard and 
experimental initiation infant formulas were offered until 6 months of 
life; then, infants received its corresponding follow-on formula from 6 to 
18 months of age. The pediatrician recommended a pattern of comple-
mentary feeding introduction and content according to Spanish Asso-
ciation of Pediatrics (Lázaro-Almarza & Benjamín, 2010). 
2.2. Ethics, consent, and permissions 
This study was carried out in accordance with ethical standards 
established by the Declaration of Helsinki 2004 (World Medical Asso-
ciation General Assembly, 2004), the EEC Good Clinical Practice rec-
ommendations (document 111/3976/88 July 1990) and the Spanish 
legislation governing clinical research in humans (Royal Decree 561/ 
1993 on clinical trials). All procedures were also approved by the Ethical 
Committee of the University of Granada, the Bioethical Committees for 
Clinical Research of the Clinical University Hospital San Cecilio and the 
Mother-Infant University Hospital of Granada, as well as respective 
Ethical Committees of the Health District of Granada, Spain. All families 
were informed about all procedures during the follow-up and a signed 
informed consent was obtained from each parent or legal guardian 
before child enrolment in the study. 
2.3. Data collection 
Baseline characteristics of parents and their offspring were obtained 
using questionnaires and medical records, including parental age, 
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educational level and intelligence quotient (IQ) (Cattell’s G-Factor in-
telligence test) (Cattell, 1963; Cattell & Cattell, 1994), smoking habit 
during pregnancy, preconceptional BMI, gestational weight gain, 
gestational age and type of delivery, number of siblings, birth weight, 
length and head circumference, infant sex, days of breastfeeding and 
attendance to kindergarten. 
2.4. Infection related follow-up and further outcome measures 
Infants were followed up at 3, 4, 6, 12 and 18 months of age, and 
underwent a physical examination by an expert pediatrician. Parents 
were asked to report infectious episodes, medication, and clinic visits, 
also submitting reports and medical documents regarding infectious 
episodes and other relevant health related events on each visit. Medical 
history was completed by face-to-face interviews. 
Regarding infectious episodes, primary outcome measures were as 
follows: 1) number and duration of infectious episodes, disclosed in RTI, 
AOM, GII, and urinary tract infections (UTI), as well as other infectious 
episodes; 2) days of fever, 3) days of antibiotic treatment; 4) need for 
health care assistance; and 5) days of hospitalization. 
Longitudinal prevalence (LP) of symptoms and medication were 
calculated by dividing number of days with reported symptoms/medi-
cation by total number of registered months (Morris et al., 1996). 
2.5. Statistical analysis 
All statistical analyses were performed using IBM® SPSS Statistics® 
program, version 22.0 (SPSS Inc. Chicago, USA). Shapiro-Wilks and 
Kolmogorov-Smirnov test, as well as visual inspection of histograms, 
were applied for all variables in the COGNIS study groups to check for 
normality. Normally distributed variables were presented as mean and 
standard deviation (SD), and non-normal variables as median and 
Fig. 1. Study profile from baseline visit to 18 
months old. Participant flow-chart from baseline 
visit to 18 months. BF: Breastfed infants; D: 
Dropouts; E: Exclusions; EF: Experimental in-
fant formula; n: Sample size; SF: Standard in-
fant formula. Up to 18 months of life, a total of 
40 infants were excluded in the SF and EF 
groups as follows: 24 were excluded in the SF 
group (1 infant due to perinatal hypoxia, 1 
infant had growth deficiency, 15 infants did 
not take the infant formula, 2 had colic of the 
infant, 3 were excluded due to lactose intol-
erance, 1 infant due to digestive surgical 
intervention, and 1 infant suffered hydro-
cephalus); 16 infants were excluded in the EF 
group (2 infants presented growth deficiency, 
2 infants lactose intolerance, 11 infants did 
not take the infant formula, and 1 was 
excluded due to epileptic seizure). Further-
more, 1 infant was excluded in the BF group 
due to she/he was not exclusively breastfed.   
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interquartile range (IQR). Categorical variables were showed as fre-
quencies and percentages. Differences in prevalence of symptoms and 
infection episodes among the three COGNIS groups were tested using 
analysis of variance (ANOVA), T-test, Kruskal-Wallis rank-sum test for 
non-normal continuous variables, and Chi-square (χ2) or Fisher test for 
categorical variables. When significant differences were found between 
groups, post-hoc Bonferroni correction was applied to identify significant 
pairwise group differences. Furthermore, those variables statistically 
different between study groups (maternal IQ and educational level, and 
paternal educational level) were included as confounders in analysis of 
covariance (ANCOVA). A logistic regression model (Wald method) was 
performed to calculate Odds Ratio (OR) and 95% Confidence Intervals 
(CI) to establish influence of the study groups or confounder variables on 
incidence of infections. As confounder variables, we selected maternal 
and paternal educational level and breastfeeding after delivery as these 
items showed significant differences between study groups, and 
kindergarten attendance as a known risk factor for common childhood 
infections (Ball et al., 2002; Côté et al., 2010). P-values < 0.05 were 
considered statistically significant. 
3. Results 
Background and baseline characteristics of parents and children are 
shown in Table 2. BF group showed a significantly higher maternal IQ (P 
< 0.001) and educational level (P < 0.001), as well as higher paternal 
educational level (P = 0.003), compared to the formula groups; how-
ever, no differences in these parameters mentioned above were found 
between both formula groups. Mothers of infants participating in the EF 
group were slightly younger than those included in SF or BF groups (P =
0.068). Regarding maternal smoking during pregnancy, mothers of BF 
groups smoked in less proportion (4.70%) compared to those of both SF 
and EF groups, who were more prone to smoking habit during preg-
nancy (18.80% and 13.0%, respectively) (P = 0.098). Besides, due to the 
COGNIS study design, a statistically significant difference was detected 
in days of breastfeeding in BF group compared to formula groups (P <
0.001). It is important to note that no significant differences were found 
among study groups with respect to attendance to kindergarten at 6 
months of life (P = 0.930). 
Incidence of infectious episodes between study groups in each 
follow-up visit (6, 12 and 18 months of life) is showed in Table 3. 
Analysis revealed that need for health care seeking (pediatric visits) up 
to 18 months was lower in the EF group, reporting the lowest need for 
pediatrician consulting (P = 0.026) at 6 months and a trend to less 
hospitalization (P = 0.064) at 12 months of age, compared to the SF and 
BF groups. At 12 months of life, EF fed infants presented lower episodes 
of unspecific fever compared to BF ones (P = 0.005). Interestingly, BF 
infants reported the highest incidence of conjunctivitis compared to 
those who fed either the SF at 12 months, or the EF at 18 months (P =
0.042; P = 0.013, respectively) (Table 3). 
Regarding direct comparison between EF and SF, results showed that 
SF infants presented a trend to higher incidence of infections (P =
0.068), and more unspecific fever episodes (P = 0.049) at 6 months. At 
12 months there were significantly less infections in the EF group (P =
0.044), particularly RTI (P = 0.031) and GII (P = 0.030), than in SF fed 
infants. No significant differences between formula fed study groups 
were detected at 18 months of life (Table 3). 
Evaluation of disease evolution, longitudinal prevalence (LP) of days 
with fever, days of infection, kindergarten absenteeism and antibiotic 
administration in infants participating at 6, 12 and 18 months of age are 
shown in Table 4. When comparing between three COGNIS groups, in 
unadjusted analysis, we found that mean of infection days was lower in 
the EF fed infant group at 12 months (P = 0.048) compared to SF and BF 
groups. A lower number of fever days in the EF group was also found at 
12 months, although not in a statistically significant manner (P =
0.083). However, after adjustment for selected confounding variables 
including maternal IQ and educational level, and paternal educational 
level, no significant differences were found in those outcomes 
mentioned above (Table 4). 
After analysis comparing EF and SF, we observed that EF group 
presented less days with fever (P = 0.031) and infections (P = 0.048) 
compared to SF group at 12 months of life. Regarding these outcomes, 
after adjustment for above confounding variables, those differences did 
not remain statistically significant (Table 4). 
Overall register of infections and symptoms between baseline visit 
and 18 months showed no significant differences between study groups. 
Direct comparisons between formula groups showed, in the unadjusted 
analysis, a significant lower number of fever days (P = 0.044) and a 
slight tendency to less infectious diseases (P = 0.093) in EF infants’ 
group. However, after adjustment for confounding variables, those dif-
ferences disappeared (Table 4). Surprisingly, days of kindergarten 
absenteeism were higher in EF infants compared to SF infants (P =
0.019) after adjustment. 
Finally, to evaluate association of confounder variables on RTI and 
GII in the formula fed groups, logistic regression model (Wald method), 
adjusted by confounders (kindergarten attendance, maternal and 
paternal educational level and breastfeeding after delivery), was 
Table 1 
Nutritional composition of the Standard (SF) and Experimental (EF) Infant 
Formulas used in the COGNIS study.   














Energy (kcal/kJ) 69/288 70/294 68/285 69/290 
Proteins (g) 1.35 1.8 1.35 1.8 
Casein/whey (%) 40/60 50/50 40/60 50/50 
Carbohydrates (g) 7.97 8.5 7.56 8.1 
Lactose (g) 7.17 7.2 6.82 7.3 
Maltodextrin (g) 0.8 1.3 0.7 0.8 
Fat (g) 3.5 3.2 3.5 3.2 
LA (mg) 579 517 569 517 
ALA (mg) 49 45 49 45 
ARA (mg) – – 15.8 10.2 
DHA (mg) – – 11.2 10.2 
Gangliosides (mg/L) 1.5 1.5 9 9 
Sialic acid (mg/L) 82 80 105 105 
MFGM-10 (wt/wt) – – 10% 10% 
Nucleotides (mg) – – 2.92 2.94 
Cytidine-5′- 
Monophosphate (mg) 
– – 1.09 1.12 
Uridine-5′- 
Monophosphate (mg) 
– – 0.88 0.9 
Adenosine-5′- 
Monophosphate (mg) 
– – 0.41 0.41 
Guanosine-5′- 
Monophosphate (mg) 
– – 0.27 0.26 
Inosine-5′- 
Monophosphate (mg) 
– – 0.27 0.26 
Prebiotics     
FOS: Inulin (ratio 1:1) – – 0.4 0.4 
Probiotics     














Initiation formula: Up to 6 months of age. Follow-on formula: between 6 and 18 
months of age. ARA: Arachidonic acid; cfu: colony forming unit; DHA: Doco-
sahexaenoic acid; FOS: Fructooligosaccharides; LA: Linoleic acid; MFGM: milk 
fat globule membrane; ALA: α-Linolenic acid. Power diluted 13.5% (13.5 g in-
fant formula made up to 100 ml with water); Power diluted 14.5% (14.5 g infant 
formula made up to 100 ml with water). 
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performed (Table 5). Type of early feeding was positively associated 
with lower incidence of RTI at 12 months of life. In fact, infants who fed 
EF showed a decreased risk of suffering RTI [OR: 0.366 (95% CI: 
0.145–0.918), P = 0.030] and GII [OR: 0.325 (95% CI: 0.130–0.811), P 
= 0.016] compared to SF infants. Moreover, attendance to kindergarten 
increases the risk of suffering RTI at 6 months of life [OR: 14.812 (95% 
CI: 3.137–69,947), P = 0.001], as well as RTI and GII infections at 12 
months [OR: 3.447 (95% CI: 1.281–9.117), P = 0.014; OR: 2.561 (95% 
CI: 1.036–6.331), P = 0.042; respectively], and RTI risk at 18 months 
[OR: 2.565 (95% CI: 1.120–5.876), P = 0.026]. 
4. Discussion 
Results of the present study suggest differences in infections inci-
dence and infection-related parameters in infants at 6 months of age, 
and especially at 12 months, with better outcomes in those infants fed 
with bioactive nutrients EF compared to the SF group. In fact, there was 
a tendency in the EF group of more infants free from infections at 6 
months, as well as significant lower proportion of infants with more than 
2 infections at 12 months, compared to the SF group. Moreover, inci-
dence of GII and RTI was significantly lower in the EF group at 12 
months. Regarding BF infants, it is remarkable that there were no sig-
nificant differences compared to the formula fed infants on number of 
overall infections, fever days or antibiotic use, after adjusting for base-
line confounders. Thus, our results might suggest that infant formula 
supplemented with bioactive nutrients, including MFGM, synbiotics, LC- 
PUFAs, nucleotides, gangliosides and sialic acid, could have beneficial 
effects on defense against infections and immune system development in 
infants during their first 18 months of life. 
Breastfeeding is the best nutritional option to prevent infant 
morbidity and mortality; it is considered the gold standard for infant 
nutrition due to its health benefits for mother and child, as well as 
environmental, economic and psychosocial aspects (Ball & Wright, 
1999; Lassi et al., 2014; Ratsika et al., 2021). Breastfeeding has been 
associated with lowered incidence of all-cause and infection-related 
mortality in infants (Sankar et al., 2015). Breast milk includes a vari-
ety of functional nutrients with diverse beneficial roles, promoting 
optimal development and maturation of infant immune system. Among 
others, HMOs present in human breast milk have shown bifidogenic 
effects, leading to a persistent finger print on gut microbiota (Beghetti 
et al., 2019; Wiciński et al., 2020). Consequently, efforts are made to 
transfer nutritional and immunological benefits of breast milk to infant 
formulas in order to guarantee an optimal nutrition, in case breast 
feeding is not possible. Several functional nutrients, especially pre- and 
probiotics, as well as MFGM, are under investigation and have shown 
individually or in different combination, to interfere in a protective way 
on risk of common infant infections (Arslanoglu et al., 2007; Maldonado 
et al., 2012, 2019; Sierra et al., 2015; Timby et al., 2015). 
Results from the current analyses are consistent with other studies 
concerning infections prevention by nutritional intervention with pro-
biotics (Liu et al., 2018). Weizman et al. reported beneficial effect of 
infant formula supplemented with probiotics [B. lactis BB12 and 
L. reuteri (American Type Culture Collection 55730)] on diarrhea, but 
not on RTI, in a 12 week follow-up in 4–10 months old infants (Weizman 
et al., 2005). Another study showed a lower incidence of GII, upper RTI 
and total incidence of infections, in a 6 month follow-up of infants 6 
months old feeding a formula supplemented with probiotics 
(L. fermentum CECT5716) compared to standard formula (Maldonado 
Table 2 
Baseline characteristics of the COGNIS study participants.    
BF (n = 50) SF(n = 85) EF (n = 85) P1 P2 
Parents characteristics 
Maternal age (years)  32 (30–36.25) 32 (24.75–35.25) 30.50 (26.25–34.75) 0.068 0.651 
Maternal educational level Primary 1 (2.00)b 19 (22.40)a 19 (22.40)a <0.001 0.518 
Secondary 5 (10.00)b 28 (32.90)a 29 (34.10)a 
VT 16 (32.00) 15 (17.60) 21 (24.70) 
University 28 (56.00)b 23 (27.10)a 16 (18.80)a 
Maternal IQ (points)  111 (99–118)b 102 (92–111)a 100 (86–108)a <0.001 0.241 
Smoking during pregnancy  2 (4.70) 13 (18.80) 10 (13.00) 0.098 0.332 
Preconceptional BMI (kg/m2)  24.18 (21.75–27.61) 24.18 (21.75–27.61) 23.68 (21.14–27.30) 0.842 0.616 
GWG (kg)  6 (4–9) 7 (3.5–10) 6 (3–9.5) 0.781 0.549 
Gestational Age (weeks)  39.5 (38–40.25) 40 (38–40) 40 (39–40) 0.925 0.732 
Type of delivery Vaginal 37 (74.00) 62 (73.00) 60 (70.60) 0.899 0.865 
Caesarean 13 (26.00) 23 (27.00) 25 (29.40) 
Siblings 0 28 (56.00) 33 (38.80) 42 (49.40) 0.128 0.164 
≥1 22 (44.00) 52 (61.20) 43 (50.60) 
Paternal age (years)  35.07 ± 5.01 32.68 ± 6.89 33.31 ± 7.03 0.134 0.576 
Paternal educational level Primary 6 (12.80)b 28 (35.00)a 36 (46.20)a 0.003 0.393 
Secondary 11 (23.40) 25 (31.30) 16 (20.50) 
VT 12 (25.50) 13 (16.30) 12 (15.40) 
University 18 (38.30)b 14 (17.40)a 14 (17.90)a 
Paternal IQ (points)  108 (99–117) 108 (96–117) 102 (92–111) 0.062 0.084 
Newborn and child characteristics 
Infant sex Boy 21 (42.0) 49 (57.6) 51 (60.00) 0.105 0.755 
Girl 29 (58.0) 36 (42.4) 34 (40.00) 
Birth weight (g)  3321.20 ± 431.73 3266.25 ± 459.08 3347.76 ± 486.41 0.513 0.264 
Birth length (cm)  51 (49–51) 50 (49–52) 51 (49–52) 0.431 0.262 
Birth HC (cm)  35 (33.25–35) 35 (34–35.5) 34.25 (34–35) 0.481 0.265 
Breastfeeding (days)  420 (270–540) 8 (0–22) 7 (1–28) <0.001 0.772 
Attendance to kindergarten at 6 mo.  4 (9.5) 6 (10.0) 8 (11.6) 0.930 1.000 
Attendance to kindergarten at 12 mo.  15 (39.5) 20 (39.2) 26 (41.3) 0.971 0.850 
Attendance to kindergarten at 18 mo.  26 (70.3) 26 (54.2) 33 (58.9) 0.311 0.693 
Data are presented as n (%) for categorical data, mean ± SD for parametrically distributed variables, and median (IQRs) for non-parametrically distributed data. 
BF: Breastfed infants; SF: Standard infant formula; EF: Experimental infant formula; BMI: Body Mass Index; IQ: Intelligence quotient; mo: months of age; VT: Vocational 
training; GWG: Gestational weight gain; HC: Head circumference. 
1 p-values for overall differences between three COGNIS-groups. ANOVA for normally distributed, Kruskal-Wallis rank-sum test for non-normal continuous, and Chi- 
square or Fisher test for categorical variables. Values not sharing same suffix (a,b) are significantly different in a Bonferroni post hoc test. 
2 p-values for differences between SF and EF COGNIS-groups. T-Test for normally distributed, U Mann-Whitney test for non-normal continuous, and Chi-square or 
Fisher test for categorical variables. P-values < 0.05 are highlighted in bold. 
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et al., 2012). Similar results were also reported with prebiotic supple-
mentation as the one employed in the current study. Arlsanoglou et al. 
showed beneficial effects of a mixture of neutral scGOS/lcFOS during 
first 6 months of life in infants, showing a reduction in respiratory in-
fections and antibiotic prescription compared to SF fed infants (Arsla-
noglu et al., 2007). Similar findings of protective effect of prebiotics 
have been also reported (Bruzzese et al., 2009). A review on prebiotics 
supplemented infant formula pointed out to their ability to modify gut 
flora enhancing Bifidobacteria growth in a dose-related way, and 
lowering GII and upper RTI incidence (Moreno Villares, 2008). 
Recently, there is a focus on beneficial effects of bovine MFGM 
components to lower the incidence of diarrhea, otitis media and fever 
episodes (Hernell et al., 2016). Timby et al. showed a protective effect of 
MFGM components on AOM in infants at 6 months of age (Timby et al., 
2015). In our study, there were no significant differences regarding 
AOM incidence, neither significant difference on antibiotic use, simi-
larly as previously reported (Cohen et al., 2013). Taking into account 
that use of antibiotics may correlate to bacterial infections, results from 
the current study might suggest a higher prevention of viral infections in 
EF infants’ group. 
However, there is a debate about if early nutritional intervention is 
able to induce a priming effect on infant intestinal microbiome, which 
might be the basis of an improved immune response after ceasing sup-
plementation. On one hand, there is evidence of prebiotic supplemen-
tation bifidogenic effects (Knol et al., 2005; Scholtens et al., 2006); some 
authors claim to attribute a reduction of antibiotic prescription, fever 
and RTI after 2 years follow-up to early nutritional intervention 
(Arslanoglu et al., 2008). On the other hand, other studies did not find a 
long lasting difference after early postnatal probiotic supplementation at 
6 years follow-up (Rutten et al., 2015), or an on-going change of host 
microbiota after a probiotic intervention (Laursen et al., 2017). Results 
of the current study could not detect, however, a significant on-going 
effect between 12 and 18 months of life. This may be attributed to a 
gradual weaning of infant formula at this age. Although changes in 
children’s microbiome are possibly induced by nutritional intervention, 
these effects seem to be vanishing over time, and external influences 
overwhelm functional nutrients effects. Consequently, a priming effect 
from early nutrition cannot be established from current results either. 
Future studies on this topic should be carried out to confirm this 
hypothesis. 
As shown above, there is evidence of beneficial effects of different 
bioactive components on infections prevention. Our study employs a 
novel combination of functional nutrients simultaneously introduced in 
EF group. Thus, this offers the possibility to study their synergic effects, 
and would demonstrate a reduction of RTI and GII infection risk by 
roughly a third in a regression model at 12 months of life. However, it 
did not allow to determine which specific functional nutrient may be 
responsible for those changes that lead to modulation of host immunity, 
and subsequent appearance of infections. 
It is important to note that BF group at 12 months showed higher 
report of symptoms related to infections. In this regard, Timby et al. 
remarked that interpretation of the comparison between formula fed 
and breastfed infants have to be made with caution (Timby et al., 2015), 
as randomization is not possible due to ethical considerations. In our 
study, baseline differences, especially in social background, were found 
in the BF group in terms of higher educational level of both parents and 
higher maternal IQ. This may lead to a better and more accurate in-
fections report in BF group, particularly when there are several months 
between infection episodes and may also suggest an underestimation of 
infections incidence in the formula fed groups, where social and intel-
lectual indicators were lower compared to BF group. Moreover, BF 
mothers are probably more prone to let their children at home during or 
after mild infections to continue BF, which might explain higher overall 
rate of kindergarten absenteeism, especially significant after adjusting 
for confounders. High incidence of conjunctivitis at 12 and 18 months in 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Analysis of the number of diseases, days with fever, days of infection, days of kindergarten absenteeism and duration of antibiotic administration of the infants participating in the COGNIS project during the first 18 months 
of life, depending on the study group.    
6 
months* 
P1 P1adj P2 P2adj 12 
months†
P1 P1adj P2 P2adj 18 
months‡






0.602 0.387 0.169 0.343 1.75 ±
1.54 
0.526 0.805 0.378 0.496 1.92 ±
1.40 
0.619 0.415 0.962 0.991 4.75 ±
3.56 

















Days with fever BF 0.52 ±
1.29 
0.880 0.843 0.627 0.796 3.16 ±
3.34 
0.083 0.180 0.031 0.070 3.14 ±
5.24 
0.862 0.834 0.673 0.746 6.82 ±
8.53 

















Days of infection BF 3.09 ±
4.19 
0.480 0.941 0.939 0.897 11.81 ±
11.0a 
0.048 0.098 0.048 0.052 7.97 ±
8.39 
0.820 0.743 0.561 0.653 23.8 ±
20.8 






















0.321 0.449 0.773 0.941 2.22 ±
5.28 
0.809 0.977 0.768 0.806 2.86 ±
4.60 
0.370 0.372 0.179 0.180 5.03 ±
8.54a 





















0.602 0.280 0.123 0.183 3.55 ±
6.27 
0.321 0.297 0.235 0.326 3.97 ±
5.66 
0.996 0.988 0.948 0.958 7.62 ±
9.19 

















Data are presented as mean ± SD. P1: P-values for overall differences between COGNIS-groups. ANOVA for normally distributed variables. P1adj are univariate analysis of covariance (ANCOVA) adjusted by maternal IQ and 
educational level, and paternal educational level. Values not sharing same suffix (ab) are significantly different in a Bonferroni post hoc test. 
P2: P-values for differences between SF and EF groups. T-test for normally distributed variables. P2adj are univariate analysis of covariance (ANCOVA) between SF and EF groups, adjusted by maternal IQ and educational 
level, and paternal educational level. P-values < 0.05 are highlighted in bold. 
* BF n = 42; SF n = 60; EF n = 69; † BF n = 38; SF n = 51; EF n = 63; ‡ BF n = 37; SF n = 48; EF n = 56. BF: Breastfed infants; SF: Standard infant formula; EF: Experimental infant formula. 
** Overall uses Longitudinal prevalence (LP) calculated by dividing the number of days with reported symptoms/medication by the total number of registered months (3, 4, 6, 12 and 18 months of life). 
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accumulation of cases happened within a 3 months period of follow-up 
where mainly breastfed infants were recalled. 
Beside nutritional intervention, other environmental factors shall 
influence on infections incidence in infants. In this sense, we found a 
strong relation between the presence of RTI and GI and kindergarten 
attendance, a factor that obviously lead to an increased exposition to 
common infant infections (Nicolai et al., 2017). 
The COGNIS study is a RCT with nutritional intervention in infants 
and long-term follow-up up to 18 months, thus giving intrinsic strength 
to this study. Our investigation employed a novel formula enriched with 
diverse functional nutrients, with each of them individually being able 
to contribute to beneficial effects observed on infections incidence, and 
now investigated together. Another strength of our study was an 
extensive baseline data collection, which permitted adjusting for 
different confounder factors. However, further studies are needed to 
understand better dose and duration of probiotic supplementation (Hao 
et al., 2015), specific function of prebiotics or complex structures like 
MFGM (Fewtrell, 2015), as well as specific contribution of individual 
nutrients and their synergic effects. 
Nevertheless, there are some limitations of study design and imple-
mentation which have to be considered when interpreting results. As 
mentioned above, beside nutritional intervention, other factors do 
interfere with immunity development for which we could not account, 
as for instance family lifestyle, hygienic conditions or complementary 
feeding, although a common pattern of complementary feeding based on 
Spanish Association of Pediatrics recommendations was handed out to 
all study participants. On the other hand, especially common childhood 
infections may be taken more or less seriously, which biases parents’ 
accuracy reports. Although follow-up visits were carried out by a 
specialized pediatrician, infections record was based on caregiver’s 
collaboration and accuracy. Analysis of biological biomarkers like 
changes in stool microbiota, or saliva levels of secretory immunoglob-
ulin A may serve to overcome this limitation. Regarding dropout rate, it 
could compromise capability identifying subtle differences, a hazel of 
many clinical trials. 
5. Conclusion 
In summary, the unique combination of functional nutrients tested in 
the current study seem to prevent typical infection episodes in infants 
during their first 12 months of life, probably through modulation of host 
immune response in a positive way. Nevertheless, effects derived from 
early nutritional intervention could not be detectable later on. 
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Association of type of early feeding, and attendance to kindergarten and risk of suffering respiratory tract infections (RTI) and gastrointestinal infections (GII) at 6, 12 
and 18 months of life.   
RTI GII  
OR (95% CI) P1 OR (95% CI) P1 
6 months of life 
Attendance to kindergarten 14.812 (3.137–69.947) 0.001 N/A N/A 
Maternal educational level (Primary) 0.735 (0.157–3.446) 0.696 6.499 (0.700–60.355) 0.100 
Paternal educational level (Primary) 2.476 (0.645–9.509) 0.187 1.814 (0.151–21.804) 0.639 
Breastfeeding after delivery (No) 0.951 (0.335–2.693) 0.924 0.279 (0.035–2.240) 0.230 
EF group* 0.765 (0.326–1.795) 0.539 0.497 (0.154–1.600) 0.241 
12 months of life 
Attendance to kindergarten 3.417 (1.281–9.117) 0.014 2.561 (1.036–6.331) 0.042 
Maternal educational level (Primary) 0.387 (0.114–1.319) 0.129 1.088 (0.214–5.532) 0.919 
Paternal educational level (Primary) 0.435 (0.090–2.088) 0.298 1.798 (0.444–7.289) 0.411 
Breastfeeding after delivery (No) 2.652 (0.757–9.289) 0.127 0.484 (0.149–1.568) 0.226 
EF group* 0.366 (0.145–0.918) 0.032 0.325 (0.130–0.811) 0.016 
18 months of life 
Attendance to kindergarten 2.565 (1.120–5.876) 0.026 2.246 (0.909–5.550) 0.080 
Maternal educational level (Primary) 1.074 (0.217–5.315) 0.129 1.400 (0.262–7.490) 0.694 
Paternal educational level (Primary) 1.644 (0.490–5.517) 0.421 1.617 (0.464–5.631) 0.450 
Breastfeeding after delivery (No) 0.824 (0.288–2.360) 0.719 0.552 (0.190–1.599) 0.273 
EF group* 0.581 (0.242–1.393) 0.233 0.673 (0.282–1.608) 0.373 
CI: Confidence Interval; EF: Experimental infant formula; GII: Gastrointestinal infections; N/A: Not available; OR: Odds Ratio; RTI: Respiratory tract infections. 
1 P-values were obtained by logistic regression analysis (Wald method). Variables included in the model were: maternal and paternal educational level, breastfeeding 
after delivery, COGNIS study groups and attendance to kindergarten. P-values < 0.05 are highlighted in bold. 
* SF group as reference. 
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Dr. Jesús Jiménez and Dr. Roser De-Castellar are employees of Labo-
ratorios Ordesa, S.L. Barcelona, Spain. All the other authors declare that 
they do not have any conflict of interest. 
Acknowledgements 
Special thanks to all the parents who collaborated and granted their 
confidence upon the EURISTIKOS Excellence Centre for Paediatric 
Research, University of Granada, the children for their patience and 
their smiles. Thanks to all the collaborators of the COGNIS-team, and 
Laboratorios Ordesa, S.L. for funding support. 
References 
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Muñoz, J. A. M., Chenoll, E., Casinos, B., Bataller, E., Ramón, D., Genovés, S., 
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